On May 13, 2024, at the 33rd European Congress on Obesity (ECO) held in Istanbul, Türkiye, groundbreaking Phase 3b trial…
Read More
Eli Lilly Faces Regulatory Scrutiny Over Foundayo’s Long-Term Safety Profile
Eli Lilly has swiftly responded to concerns raised by the US Food and Drug Administration (FDA) regarding the long-term safety…
Read More
Eli Lilly’s Foundayo Secures FDA Approval, Challenging Novo Nordisk’s Oral Obesity Drug Dominance
The United States Food and Drug Administration (FDA) has granted approval to Eli Lilly and Company’s novel oral glucagon-like peptide-1…
Read MoreYOU MAY HAVE MISSED
